PDF(Pubmed)
Abstract：
OBJECTIVE: This study evaluates the long-term adjunctive use of netarsudil ophthalmic solution 0.02% in lowering IOP in patients with refractory glaucoma.
METHODS: This retrospective chart review study was conducted at a tertiary care center. Patients who were prescribed add-on netarsudil therapy and on ≥ 3 topical glaucoma medications from 01/01/2018 to 08/31/2020 were reviewed. 47 patients (69 eyes) met the inclusion criteria. Baseline IOPs prior to the addition of netarsudil were compared to IOPs measured at 3-, 6-, and 12-month intervals. Any patients with inadequate follow-up or who had glaucoma surgery after netarsudil initiation were excluded.
RESULTS: Median baseline IOP (± SD) was 21 ± 5.8 mmHg (median of 2 visits prior to initiation of netarsudil). At 3-month follow-up, 64 eyes had a median IOP of 16 ± 6.7 mmHg (p < 0.01). At 6-month follow-up, 56 eyes had a median IOP of 18 ± 4.6 mmHg (p < 0.01). At 12-month follow-up, 44 eyes had a median IOP of 15 ± 6.8 mmHg (p < 0.01). At the conclusion of the study, 64% of eyes reached 1 year follow-up due to several reasons.
CONCLUSIONS: Patients with refractory glaucoma showed statistically and clinically significant IOP reductions on netarsudil. IOP reduction was stable long-term with the largest decrease in IOP seen at 12 months. Although some patients will still go on to require further laser or incisional surgery, for most patients netarsudil is an effective treatment for adjunctive use in refractory glaucoma.
METHODS: This retrospective chart review study was conducted at a tertiary care center. Patients who were prescribed add-on netarsudil therapy and on ≥ 3 topical glaucoma medications from 01/01/2018 to 08/31/2020 were reviewed. 47 patients (69 eyes) met the inclusion criteria. Baseline IOPs prior to the addition of netarsudil were compared to IOPs measured at 3-, 6-, and 12-month intervals. Any patients with inadequate follow-up or who had glaucoma surgery after netarsudil initiation were excluded.
RESULTS: Median baseline IOP (± SD) was 21 ± 5.8 mmHg (median of 2 visits prior to initiation of netarsudil). At 3-month follow-up, 64 eyes had a median IOP of 16 ± 6.7 mmHg (p < 0.01). At 6-month follow-up, 56 eyes had a median IOP of 18 ± 4.6 mmHg (p < 0.01). At 12-month follow-up, 44 eyes had a median IOP of 15 ± 6.8 mmHg (p < 0.01). At the conclusion of the study, 64% of eyes reached 1 year follow-up due to several reasons.
CONCLUSIONS: Patients with refractory glaucoma showed statistically and clinically significant IOP reductions on netarsudil. IOP reduction was stable long-term with the largest decrease in IOP seen at 12 months. Although some patients will still go on to require further laser or incisional surgery, for most patients netarsudil is an effective treatment for adjunctive use in refractory glaucoma.
摘要：
目的：本研究评估了长期使用依塔舒地尔滴眼液0.02％降低难治性青光眼患者眼压的效果。
方法：本回顾性图表综述研究在三级护理中心进行。对从2018年1月1日至2020年8月31日接受内塔舒地尔附加治疗和≥3种局部青光眼药物的患者进行了回顾。47例患者（69只眼）符合纳入标准。基线IOPs前的添加netarsudil比较IOPs测量在3,6-，和12个月的间隔。排除任何随访不足或在netarsudil开始后进行青光眼手术的患者。
结果：基线眼压中位数（±SD）为21±5.8mmHg（在开始服用netarsudil之前2次就诊的中位数）。在3个月的随访中，64只眼的中位眼压为16±6.7mmHg(p<0.01)。在6个月的随访中，56只眼的中位眼压为18±4.6mmHg(p<0.01)。在12个月的随访中，44只眼的中位眼压为15±6.8mmHg(p<0.01)。在研究结束时，由于多种原因，64％的眼睛获得了1年的随访。
结论：难治性青光眼患者服用netarsudil后眼压显著降低。IOP降低是长期稳定的,在12个月时观察到最大的IOP降低。尽管有些患者仍需要进一步的激光或切口手术，对于大多数患者来说，netarsudil是难治性青光眼辅助使用的有效治疗方法。
方法：本回顾性图表综述研究在三级护理中心进行。对从2018年1月1日至2020年8月31日接受内塔舒地尔附加治疗和≥3种局部青光眼药物的患者进行了回顾。47例患者（69只眼）符合纳入标准。基线IOPs前的添加netarsudil比较IOPs测量在3,6-，和12个月的间隔。排除任何随访不足或在netarsudil开始后进行青光眼手术的患者。
结果：基线眼压中位数（±SD）为21±5.8mmHg（在开始服用netarsudil之前2次就诊的中位数）。在3个月的随访中，64只眼的中位眼压为16±6.7mmHg(p<0.01)。在6个月的随访中，56只眼的中位眼压为18±4.6mmHg(p<0.01)。在12个月的随访中，44只眼的中位眼压为15±6.8mmHg(p<0.01)。在研究结束时，由于多种原因，64％的眼睛获得了1年的随访。
结论：难治性青光眼患者服用netarsudil后眼压显著降低。IOP降低是长期稳定的,在12个月时观察到最大的IOP降低。尽管有些患者仍需要进一步的激光或切口手术，对于大多数患者来说，netarsudil是难治性青光眼辅助使用的有效治疗方法。
